{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-035939","form_type":"8-K","ticker":null,"cik":"0001693011","company_name":"Inozyme Pharma, Inc.","filed_at":"2025-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.475374+00:00","generated_at":"2026-05-25T01:45:05.655698+00:00","sec_items":["2.02","2.05","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Inozyme reports FY2024 net loss of $102M; cuts 25% workforce to focus on ENPP1 Deficiency","bullets":["FY2024 net loss $102.0M ($1.62 per share) vs $71.2M ($1.37 per share) in 2023.","Cash, equivalents & ST investments $113.1M; expects runway into Q1 2026 after prioritization.","Workforce reduction of ~25%; $1.8M expected charges, substantially complete by Q3 2025.","Completed enrollment in ENERGY 3 trial (N=27) for INZ-701; topline data expected Q1 2026.","ABCC6 Deficiency and calciphylaxis trials postponed; only ongoing treatment for existing patients continues."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-035939","json":"https://secwatch.observer/filing/0000950170-25-035939.json","markdown":"https://secwatch.observer/filing/0000950170-25-035939.md","text":"https://secwatch.observer/filing/0000950170-25-035939.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1693011/000095017025035939/0000950170-25-035939-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1693011/000095017025035939/inzy-20250307.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T01:45:05.655698+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"38f7fdee62a2a539a4591d50ed6b4b43381930e1","claim":"Inozyme Pharma, Inc. announced a restructuring with charges of approximately $1.8 million affecting all areas of the Company (approximately 25%).","evidence_excerpt":"On March 7, 2025, the Company's Board of Directors approved a reduction of the Company’s workforce by approximately 25% across all areas of the Company, as part of the Company’s decision to prioritize activities to support the planned Biologics License Application filing for INZ-701 for the Company’s lead indication, ENPP1 Deficiency. The Company expects to incur approximately $1.8 million in connection with the workforce reduction, which primarily represents one-time employee termination benefits directly associated with the workforce reduction.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1693011/000095017025035939/0000950170-25-035939-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $1.8 million"},{"label":"Affected area","value":"all areas of the Company"},{"label":"Headcount","value":"approximately 25%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}